Abstract 1595
Background
Recent evidence supported that netrin-1 involves in colorectal carcinogenesis. This study was to evaluate the performance of serum netrin-1 for detection of colorectal cancer (CRC) in both a clinical set and a screening set.
Methods
A total of 115 consecutive patients with CRC and matched healthy controls were included in Clinical Set. Fifty subjects with CRC, 50 subjects with advanced adenoma (AA), and 150 matched control participants free of neoplasia were included in Screening Set. Circulating levels of netrin-1 were evaluated with commercial ELISA kits.
Results
In Clinical set, subjects with CRC presented higher levels of serum netrin-1 (513.9 ± 22.6 pg/mL) than controls (347.8 ± 20.3 pg/mL, p < 0.0001). Similar in Screening set, serum levels of netrin-1 was higher in CRC (644.5 ± 37.0 pg/mL), in comparison with controls (407.7 ± 14.8 pg/mL, p < 0.0001) and AA (416.5 ± 18.5 pg/mL, p < 0.0001). However, there was no difference between controls and AA (p = 0.752). Compared with the low netrin-1 group, the high group presented increased risk of CRC (Clinical set: OR = 4.300 [95% CI 2.473 – 7.477], p < 0.001); Screening set: OR = 7.731 [95% CI 3.618 – 16.519], p < 0.001). ROC curve of netrin-1 was developed to detect CRC (Clinical set: AUC 0.703 [95% CI 0.636 – 0.770]; Screening set: AUC 0.759 [95% CI 0.680 – 0.837]).Table: 147P
Study population characteristics
Clinical set | Screening set | ||||
---|---|---|---|---|---|
Controls | CRC | Controls | AA | CRC | |
Number | 115 | 115 | 150 | 50 | 50 |
Netrin-1 levels (pg/ml) | 347.8 ± 20.3* | 513.9 ± 22.6* | 407.7 ± 14.8# | 416.5 ± 18.5^ | 644.5 ± 37.0#^ |
Age (years) | 53.8 ± 8.7 | 55.9 ± 9.1 | 54.2 ± 9.2 | 51.9 ± 10.0 | 55.8 ± 9.6 |
Sex | |||||
Male | 92 | 92 | 111 | 37 | 37 |
Female | 23 | 23 | 39 | 13 | 13 |
BMI (kg/m2) | 22.8 ± 3.0 | 24.6 ± 3.9 | 22.4 ± 2.9 | 23.1 ± 3.1 | 23.7 ± 3.1 |
WHR | 0.89 ± 0.08 | 0.92 ± 0.06 | 0.88 ± 0.08 | 0.94 ± 0.09 | 0.99 ± 0.07 |
TNM stage | |||||
I | 16 | 10 | |||
II | 43 | 22 | |||
III | 42 | 13 | |||
IV | 14 | 5 | |||
Location | |||||
Colon | 83 | 34 | |||
Rectum | 32 | 16 |
Data are mean ± SD for continuous variables.
*p < 0.001; #p < 0.001; ∧p < 0.001. AA, advanced adenomas; BMI, body mass index; WHR, waist-to-hip circumference ratio.
Conclusions
It suggests netrin-1 as a potential biomarker in the screening and detection of CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital of Soochow University.
Funding
Jiangsu Provincial Key Research and Development Plan (No. BE2018659) and Provincial Key Laboratory Program of Higher Education (No. KJS1867).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract